Dublin, March 21, 2024 (GLOBE NEWSWIRE) -- The "Acute Myeloid Leukemia (AML) KOL Interview - US, South" report has been added to ResearchAndMarkets.com's offering. This report presents an exclusive ...
KOMET-007 insights show ziftomenib’s manageable toxicity, low QTc risk, and easy oral dosing, supporting long-term AML ...
Ziftomenib combinations show promising frontline AML results, expanding trials with chemo and targeted partners; phase 3 aims ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results